First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time 

January 25, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand

Date of Release: March 1, 2022

Expiration Date: March 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

Course Description:

In this session, Drs. Janessa Laskin and Laura Williamson will present a case of a 64-year-old female diagnosed with metastatic lung neuroendocrine carcinoma. She had been treated with chemotherapy and radiation, with some response but subsequent growth in multiple locations. Whole genome and transcriptome analysis of a metastatic chest wall mass was performed as part of the Personalized OncoGenomics Study. Molecular analysis revealed no targetable driver mutations and low tumour mutation burden, but gene expression signatures provided evidence for T cells and macrophages in the tumour sample. The combination of biomarkers made this patient eligible for an immunotherapy trial. An additional case with similar gene expression signatures, a pediatric chordoma patient found to have low tumour mutation burden but high tumour T cell infiltration, subsequently responded to immunotherapy. The use of whole genome and transcriptome profiling to examine the immune microenvironment and biomarkers for immunotherapy response will be reviewed. The design of an immunotherapy trial based on both DNA and RNA molecular markers will be discussed

Target Audience:

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic and VICC consortia, and ACMG.

Learning Objectives:

At the conclusion of this session, participants should be able to:

1. Describe the genomic methods used to care for this patient
2. Discuss the nature of biomarkers that confer sensitivity to immunotherapy
3. Explain the of role T cell infiltration in the absence of high tumor mutational burden

Janessa Laskin, MD

Medical Oncologist at the British Columbia Cancer Agency

Clinical Associate Professor of Medical Oncology at the University of British Columbia, Vancouver, Canada

Dr. Laskin is a clinical Associate Professor in the Department of Medicine at the University of British Columbia and an active member of the medical oncology staff at BC Cancer Agency in Vancouver, Canada. Her clinical and research interests have primarily focused on lung and head and neck cancers. She is an active member of many national and international lung cancer trials and advisory groups. In the last decade her research has evolved towards cancer genomics and personalized medicine and she is the clinical program leader for the Personalized OncoGenomics (POG) Program which is a collaborative research project between medical oncologists and Michael Smith Genome Sciences Centre in Vancouver. The POG program is truly translational research effort that uses in-depth genomic and transcriptome sequencing to guide chemotherapy decision-making in a clinically relevant time-frame.

Laura Williamson, PhD

Clinical Informatics Team Lead, Michael Smith Genome Sciences Centre, Vancouver, Canada

Dr. Laura Williamson is Clinical Informatics Team Lead at Michael Smith Genome Sciences Centre in Vancouver, Canada. In this role, she leads genome analysts that coalesce and interpret data generated from high throughput bioinformatic analyses of patient tumor sequencing data, in particular for BC Cancer Personalized OncoGenomics (POG) program, the Terry Fox Research Institute Precision Oncology for Young People (PROFYLE) project and Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis (PanGen) study. The Clinical Informatics team also supports bioinformatics groups in the development and implementation of methods of integrative analysis and collaborates with clinicians to promote knowledge translation.

Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jane Radford, MHA, CHCP

CME Educational Credits:

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net